FDA’s approval of LEQEMBI
2023 marked a significant milestone in Alzheimer’s disease (AD) treatment with the FDA’s approval of LEQEMBI (lecanemab-irmb). This groundbreaking treatment, developed by Eisai Co., Ltd. and Biogen Inc., showed substantial efficacy in reducing disease progression and slowing cognitive decline in early-stage AD patients. LEQEMBI’s approval is particularly noteworthy as it is the first treatment proven to affect the disease’s course.